Agios Pharmaceuticals Inc stock is traded at $31.59, with a volume of 371,336. It is down -0.54% in the last 24 hours and up +0.86% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Previous Close:
$31.76
Open:
$31.64
24h Volume:
371,336
Relative Volume:
0.32
Market Cap:
$1.89B
Revenue:
$66.05M
Net Income/Loss:
-$422.60M
P/E Ratio:
-
EPS:
-$7.25
Net Cash Flow:
-$384.73M
1W Performance:
+0.67%
1M Performance:
+0.86%
6M Performance:
+12.14%
1Y Performance:
-27.63%
1-Day Range:
$30.81$31.97
1-Week Range:
$30.48$33.12
52-Week Range:
$22.24$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
617-649-8600Address
88 SIDNEY STREET, CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS